-

Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities

-    Company has provided more than $3.7 million to COVID-19 response and relief efforts    -

LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has provided $1.2 million in additional funding to U.S and international organizations to support COVID-19 relief efforts, including: The Chicago Community Trust, The Lake County Community Foundation, Silicon Valley Community Foundation, Greater Washington Community Foundation, Americares, ALONE, Family Carers Ireland, Enable Ireland and Toronto Foundation.

Throughout 2020, Horizon has also provided more than $1 million to advocacy organizations to support COVID-19 relief initiatives for people living with rare and rheumatic diseases. This includes educational resources, emergency financial relief and internet connectivity to facilitate continued care via telehealth.

“We recognize that the COVID-19 pandemic is currently impacting more families, communities and organizations than ever before,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “As a global company, we believe it is our fundamental responsibility to support these foundations and organizations so they can thrive and continue to help the communities they serve.”

“While the devastating health and economic crises caused by COVID-19 has disproportionately impacted Chicago’s Black and Latinx communities, we have a once-in-a-generation opportunity to build a more equitable recovery,” said Dr. Helene Gayle, president, chief executive officer, The Chicago Community Trust. “We are grateful for the support of Horizon Therapeutics as we know it’s going to take an unprecedented coalition, across philanthropy, business and communities, to transform the systems that have held back communities of color for centuries.”

“Horizon Therapeutics is among Americares most dedicated partners, consistently providing product donations and annual support that helps us prepare for and respond to emergencies, and fuels our ongoing health programs,” said Christine Squires, president, chief executive officer, Americares. “This donation will allow us to support U.S. safety net clinics as they leverage telehealth technology so patients can access the care they need from home, without worrying about putting themselves or others at risk of COVID-19 infection.”

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Contacts

U.S. Media Contact:
Geoff Curtis
Executive Vice President, Corporate Affairs and Chief Communications Officer
media@horizontherapeutics.com

Investor Contacts:
Tina Ventura
Senior Vice President, Investor Relations
Investor-relations@horizontherapeutics.com

Ruth Venning
Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com

Ireland Media Contact:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie

Horizon Therapeutics plc

NASDAQ:HZNP

Release Versions

Contacts

U.S. Media Contact:
Geoff Curtis
Executive Vice President, Corporate Affairs and Chief Communications Officer
media@horizontherapeutics.com

Investor Contacts:
Tina Ventura
Senior Vice President, Investor Relations
Investor-relations@horizontherapeutics.com

Ruth Venning
Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com

Ireland Media Contact:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie

More News From Horizon Therapeutics plc

Rule 17(e) Announcement - Horizon Therapeutics plc

DUBLIN--(BUSINESS WIRE)--  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of...

Rule 17(d) Announcement – Horizon Therapeutics plc

DUBLIN--(BUSINESS WIRE)--  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies A...

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

DUBLIN--(BUSINESS WIRE)--IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Elizabeth Crossan (b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficien...
Back to Newsroom